Orphazyme (1TB.F) Stock Highlights

164.5 | -0.6%

2024-01-11 03:28:40

Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The companys lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Statistics

Range Today

164.5 164.5

Volume Today 0

Range 1 Year

84.8 457.5

Volume 1 Year 40

Range 3 Year

84.8 16500

Volume 3 Year 368

Range 10 Year

84.8 91900

Volume 10 Year 378

Highlights

Market Capitalization 37.27M (micro)

Floating Shares 25.8K

Current Price 164.5

Price To Earnings 0

Price To Book 0

Earnings Per Share -2.29K

Payout Ratio 0%

Performance

Latest -0.6%

1 Month +83.8%

3 Months +40.12%

6 Months -21.48%

1 Year +47.4%

3 Years -98.11%

5 Years -97.32%

10 Years -97.32%

Benchmarks

Market Capitalization

0 / 368

Gross Profits

0 / 278

Total Revenue

0 / 300

Total Rank

0 / 368

Free Cashflow

0 / 352

Performance 5 years

0 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.